文献速递淋巴瘤

复发难治性外周T细胞淋巴瘤:单药与联合化疗比较(COMPLETE注册研究)

Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry.
PubMed 文献 · Am J Hematol · 2019-04-09

COMPLETE注册研究纳入57例复发难治性外周T细胞淋巴瘤患者,首次再治疗时46%(26/57)接受联合化疗、54.5%(31/57)接受单药。中位随访2年,单药组完全缓解率41% vs 联合组19%(P=.02),中位总生存38.9 vs 17.1个月(P=.02),无进展生存11.2 vs 6.7个月(P=.02)。

要点

  • 复发难治性PTCL首次再治疗,单药组完全缓解率41% vs 联合化疗组19%(P=.02)。
  • 单药组中位总生存38.9个月 vs 联合组17.1个月(P=.02)。
  • 单药组接受造血干细胞移植比例25.8% vs 联合组7.7%(P=.07)。

核心结论

  • 数据证实复发难治性PTCL存在未满足的更好治疗需求。
  • 尽管样本量小,分析显示在复发难治背景下以单药作为首次再治疗者缓解和生存更优,同时保持实现移植的能力。
  • 需要大型随机试验来确定最佳策略。

研究设计与样本

  • COMPLETE注册研究,纳入组织学确诊的PTCL患者。
  • 合格标准为复发难治性疾病、已接受一种既往全身治疗、并以单药或联合化疗作为首次再治疗。
  • 共57例患者符合标准,首次再治疗时46%(26/57)接受联合化疗、54.5%(31/57)接受单药。
  • 主要终点为再治疗的最佳缓解。

主要发现

  • 中位随访2年,单药组完全缓解率41% vs 联合化疗组19%(P=.02),呈升高趋势。
  • 单药组中位总生存38.9个月 vs 联合组17.1个月(P=.02)。
  • 单药组中位无进展生存11.2个月 vs 联合组6.7个月(P=.02)。
  • 单药组接受造血干细胞移植比例25.8% vs 联合组7.7%(P=.07)。
  • 3级或4级不良事件在联合化疗组更常见,但未达统计学显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出样本量小(small sample)。
  • 原文结论提出需要大型随机试验来确定最佳策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Single agents have demonstrated activity in relapsed and refractory (R/R) peripheral T-cell lymphoma (PTCL). Their benefit relative to combination chemotherapy remains undefined. Patients with histologically confirmed PTCL were enrolled in the Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) registry. Eligibility criteria included those with R/R disease who had received one prior systemic therapy and were given either a single agent or combination chemotherapy as first retreatment. Treatment results for those with R/R disease who received single agents were compared to those who received combination chemotherapy. The primary endpoint was best response to retreatment. Fifty-seven patients met eligibility criteria. At first retreatment, 46% (26/57) received combination therapy and 54.5% (31/57) received single agents. At median follow up of 2 years, a trend was seen towards increased complete response rate for single agents versus combination therapy (41% vs 19%; P = .02). There was also increased median overall survival (38.9 vs 17.1 months; P = .02) and progression-free survival (11.2 vs 6.7 months; P = .02). More patients receiving single agents received hematopoietic stem-cell transplantation (25.8% vs 7.7%, P = .07). Adverse events of grade 3 or 4 occurred more frequently in those receiving combination therapy, although this was not statistically significant. The data confirm the unmet need for better treatment in R/R PTCL. Despite a small sample, the analysis shows greater response and survival in those treated with single agents as first retreatment in R/R setting, while maintaining the ability to achieve transplantation. Large, randomized trials are needed to identify the best strategy.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Stuver RN, Khan N, Schwartz M, et al. Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry. Am J Hematol. 2019. PMID: 30896890. doi:10.1002/ajh.25463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。